12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oncophage vitespen: Interim extension study data

Interim survival data from the INSPIRE patient registry, which is an extension of the open-label, international Phase III C-100-12 trial in 362 evaluable RCC patients at intermediate risk of recurrence, showed that patients receiving Oncophage had about a 46% lower risk of death vs. observation alone (p=0.036). Specifically, there were 18/184 (9.8%) deaths in the Oncophage arm vs. 32/178 (18%) deaths in the observation arm. In...

Read the full 310 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >